Skip to main content
SpringerLink
Log in

Role of Desensitisation for Drug Hypersensitivity in Patients with HIV Infection

  • Review Articles
  • Drug Safety Concepts
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Drug hypersensitivity is common in patients with HIV infection and manifests as a delayed onset maculopapular rash, often with fever, mucositis and occasionally visceral involvement. In the 50% of patients who require treatment modification, many can be treated with an equally effective alternative that does not cause hypersensitivity. For the remainder, options include ‘treating through’ the reaction, adjunctive corticosteroids and/or antihistamines, rechallenge and desensitisation. Formal comparisons are lacking but preliminary data suggest that desensitisation is more sucessful than rechallenge. The most common reason for performing desensitisation is sulphonamide hypersensitivity for treatment or prophylaxis of pneumocystosis, where success rates of 68 to 100% have been reported. Success seems more likely when regimens lasting 7 or more days are used and in patients with lower CD4+ lymphocyte counts. However, the best tolerated, effective and simple desensitisation regimen has not been determined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mitsuyasu R, Groopman J, Volberding P. Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi’s sarcoma [letter]. N Engl J Med 1983; 308: 1535–6

    Article  PubMed  CAS  Google Scholar 

  2. Jaffe HS, Abrams DI, Ammann AJ, et al. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1983; I: 1109–11

    Article  Google Scholar 

  3. Coopman MA, Johnson RA, Platt R, et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328: 1670–4

    Article  PubMed  CAS  Google Scholar 

  4. Roujeau J-C, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272–85

    Article  PubMed  CAS  Google Scholar 

  5. Carr A, Cooper DA. Pathogenesis and management of HIV-associated drug hypersensitivity. In: Volberding P, Jacobson MA, editors. AIDS Clinical Review 1995/1996. New York: Marcel Dekker, 1996: 65–98

    Google Scholar 

  6. Schneider MME, Hospelman AIM, J Karel, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolised pentamidine as primary prophylaxis of Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327: 1836–41

    Article  PubMed  CAS  Google Scholar 

  7. Gordin FM, Simon GL, Wofsy CB, et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 495–9

    PubMed  CAS  Google Scholar 

  8. Arnold PA, Guglielmo BJ, Hollander H. Severe hypersensitivity reaction upon rechallenge with trimethoprim-sulfamethoxazole in a patient with AIDS. Drug Intell Clin Pharm 1988; 22: 43–5

    PubMed  CAS  Google Scholar 

  9. Silvestri RC, Jensen WA, Zibrak JD, et al. Pulmonary infiltrates and hypoxaemia in patients with the acquired immune deficiency syndrome re-exposed to trimethoprim-sulfamethoxazole. Am Rev Respir Dis 1987; 136: 1003–4

    Article  PubMed  CAS  Google Scholar 

  10. Kovacs JA, Hiementz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100: 66–71

    Google Scholar 

  11. Jick J. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 1982; 4: 426–8

    Article  PubMed  CAS  Google Scholar 

  12. Lau WK, Young LS. Trimethoprim-sulfamethoxazole treatment of Pneumocystis carinii pneumonia in adults. N Engl J Med 1976; 295: 716–8

    Article  PubMed  CAS  Google Scholar 

  13. Winston DJ, Lau WK, Young LS. Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med 1980; 92: 762–9

    PubMed  CAS  Google Scholar 

  14. Sattler FR, Cowan R, Nielsen DM, et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective non-crossover study. Ann Intern Med 1988; 109:280–7

    PubMed  CAS  Google Scholar 

  15. Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulphamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105: 37–44

    PubMed  CAS  Google Scholar 

  16. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323: 776–82

    Article  PubMed  CAS  Google Scholar 

  17. Carr A, Swanson C, Penny R, et al. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993; 167: 180–5

    Article  PubMed  CAS  Google Scholar 

  18. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonitis in patients with AIDS. N Engl J Med 1993; 328: 1521–7

    Article  PubMed  CAS  Google Scholar 

  19. CDC. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR 1992; 41: 1–11

    Google Scholar 

  20. Carr A, Tindall B, Brew B, et al. Low dose trimethoprim-sulfamethoxazole prophylaxis against toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992; 117: 106–11

    PubMed  CAS  Google Scholar 

  21. Carr A, Tindall B, Penny R, et al. Multiple drug hypersensitivity in patients with HIV disease [letter]. AIDS 1993; 7: 1532–3

    Article  PubMed  CAS  Google Scholar 

  22. Carr A, Vasak E, Munro V, et al. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clin Exp Immunol 1994; 97: 250–3

    Google Scholar 

  23. Greenberger PA, Patterson R. Management of drug allergy in patients with acquired immunodeficiency syndrome. J Allergy Clin Immunol 1987; 79: 484–8

    Article  PubMed  CAS  Google Scholar 

  24. Aguilar X, Ruiz J, Clotet B, et al. The use of corticosteroids in the control of adverse effects of cotrimoxazole in AIDS patients suffering with PCP [letter]. AIDS 1991; 5: 777–8

    Article  PubMed  CAS  Google Scholar 

  25. Hennessy S, Strom BL, Berlin JA, et al. Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV-infected individuals receiving primary Pneumocystis carinii pneumonia prophylaxis. J Gen Intern Med 1995; 10: 380–6

    Article  PubMed  CAS  Google Scholar 

  26. Montaner JSG, Lawson LM, Levitt N, et al. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 113: 14–20

    PubMed  CAS  Google Scholar 

  27. Gagnon S, Boota AM, Fischl MA, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a double blind, placebo-controlled trial. N Engl J Med 1990; 323: 1444–50

    Article  PubMed  CAS  Google Scholar 

  28. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 1451–7

    Article  PubMed  CAS  Google Scholar 

  29. Clark DW. Variability in drug acetylation and oxidation: therapeutic implications. Drugs 1985; 29: 342–75

    Article  PubMed  CAS  Google Scholar 

  30. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1992; 41: RR–4

    Google Scholar 

  31. Shafer RW, Seitzmann PA, Tapper ML. Successful prophylaxis of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole in AIDS patients with previous allergic reactions. J Acquir Immune Defic Syndr 1989; 2: 389–93

    PubMed  CAS  Google Scholar 

  32. Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low dose trimethoprim-sulphamethoxazole of previously hypersensitive HIV-infected patients. AIDS 1993; 7: 65–71

    Article  PubMed  CAS  Google Scholar 

  33. Gluckstein D, Ruskin J, Nielsen D. Oral desensitisation to trimethoprim-sulfamethoxazole in hypersensitive AIDS patients: utility in trimethoprim-sulphamethoxazole prophylaxis of Pneumocystis carinii pneumonia [abstract]. 4th International Conference on AIDS: 1988 Jun 20–24; Stockholm, A7176

  34. Finegold I. Oral desensitisation to trimethoprim-sulfamethoxazole in a patient with acquired immunodeficiency syndrome. J Allergy Clin Immunol 1986; 78: 905–8

    Article  PubMed  CAS  Google Scholar 

  35. Absar N, Danashevar H, Beall G. Desensitisation to trimethoprim-sulfamethoxazole in HIV-infected patients. J Allergy Clin Immunol 1994; 93: 1001–5

    Article  PubMed  CAS  Google Scholar 

  36. Gilquin J, Piketty C, Kazatchkine MD. Efficacy and safety of trimethoprim-sulfamethoxazole desensitisation in HIV-infected patients [abstract]. 10th International Conference on AIDS: 1994 Aug 7–12; Yokohama, PB0616

  37. Belchi-Hernandez J, Espinosa-Parra FJ. Management of adverse reactions to prophylactic trimethoprim-sulphamethoxazole in patients with human immunodeficiency virus infection. Ann Allergy Asthma Immunol 1996; 76: 355–8

    Article  PubMed  CAS  Google Scholar 

  38. Nguyen MT, Weiss PJ, Wallace MR. Two-day oral desensitization to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS 1995; 9: 573–5

    Article  PubMed  CAS  Google Scholar 

  39. Bachmeyer C, Salmon D, Guerin C, et al. Trimethoprim-sulphamethoxazole desensitisation in HIV-infected patients [letter]. AIDS 1995; 9: 299–300

    PubMed  CAS  Google Scholar 

  40. Piketty C, Gilquin J, Kazatchkine MD. Efficacy and safety of desensitization to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients [letter]. J Infect Dis 1995; 172: 611

    Article  PubMed  CAS  Google Scholar 

  41. Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995; 20: 849–53

    Article  PubMed  CAS  Google Scholar 

  42. Bissuel F, Cotte L, Crapanne JB, et al. Trimethoprim-sulphamethoxazole rechallenge in 20 previously allergic HIV-infected patients. AIDS 1995; 9: 407–8

    Article  PubMed  CAS  Google Scholar 

  43. Tenant-Flowers M, Boyle M, Carey D, et al. Sulphadiazine desensitisation in patients with AIDS and cerebral toxoplasmosis. AIDS 1991; 5: 311–5

    Article  PubMed  CAS  Google Scholar 

  44. Bell ET, Tapper ML, Pollock AA. Sulphadiazine desensitisation in AIDS patients [letter]. Lancet 1985; I: 163

    Article  Google Scholar 

  45. Metroka CE, Lewis NJ, Jacobus DP. Desensitization to dapsone in HIV-positive patients [letter]. JAMA 1992; 267: 512

    Article  PubMed  CAS  Google Scholar 

  46. Caumes E, Guermonprez G, Lecomte C, et al. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Arch Dermatol 1997; 133: 465–9

    Article  PubMed  CAS  Google Scholar 

  47. Dohn M, Frame P, Becker S, et al. ACTG 268 trial: gradual introduction of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia [abstract]. 4th Conference on Retroviruses and Opportunistic Infections: 1997 Jan 29-Feb 2; Washington, DC

  48. Carr A, Vella S, de Jong MD, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS 1996; 10: 635–41

    Article  PubMed  CAS  Google Scholar 

  49. Carr A, Penny R, Cooper DA. Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS). J Allergy Clin Immunol 1993; 91: 683–5

    Article  PubMed  CAS  Google Scholar 

  50. Caumes E, Guermonprez G, Winter C, et al. A life-threatening reaction to trimethoprim-sulfamethoxazole desensitization in an HIV-infected patient [letter]. Clin Infect Dis 1996; 23: 1313–4

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Andrew Carr, HIV Medicine Unit, St Vincent’s Hospital, Sydney, New South Wales, 2010, Australia

    Andrew Carr

Authors
  1. Andrew Carr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Carr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carr, A. Role of Desensitisation for Drug Hypersensitivity in Patients with HIV Infection. Drug-Safety 17, 119–126 (1997). https://doi.org/10.2165/00002018-199717020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199717020-00004

Keywords

Search

Navigation